Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ValiRx trial group receives cancer treatment with no adverse effects

VAL201 is being developed to treat hormone-resistant prostate cancer and is currently undergoing a phase I/II study.
ValiRx trial group receives cancer treatment with no adverse effects
VAL201 is being developed to tackle prostate cancer.

ValiRx (LON:VAL) said a further group of patients receiving VAL201 have completed the clinical trial dosing sequence with no significant adverse effects.

VAL201 is being developed to treat hormone-resistant prostate cancer and is currently undergoing a phase I/II study.

The latest feedback echoes that from an earlier cohort on a lower dose of the medication. ValiRx will now be allowed to increase the amount of VAL201 administered to cancer sufferers one last time to assess its impact.

“The company believes that being able to dose patients at levels and with a frequency that matches the pre-clinical validated amounts that are therapeutically relevant, represents another important milestone,” ValiRx said in a short stock exchange statement.

The firm will provide updates as the trial progresses. Eagerly awaited will be any hint of efficacy. Researchers saw “tumour modulating effects” pre-clinically and they have been “hinted at during the in-human stage”.

Ian_55ae0ddd437b7.jpg
Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

genomics.jpg
October 04 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.
a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017
picture of pregnant women
May 09 2017
Diclectin is entering a potential £250mln UK/European market with a differentiated product addressing an unmet need.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use